AnaptysBio (ANAB)

• Market cap: $1.53B
• 1 day: -1.5%
• 5 days: 1.94%
• 1 month: 11.14%
• 3 months: 32.7%
• 6 months: 170.93%
• Year to date: 22.96%
• 1 year: 237.01%
• 5 years: 97.04%
• 10 years: 225.12%
• Sector: Healthcare
• Industry: Biotechnology

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136